News Search Results
Jan 09, 2026, 08:00 ET Curis Announces Closing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in a Phase 2 study (CA-4948-203) of emavusertib in
More news about: Curis, Inc.
Jan 08, 2026, 16:05 ET ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates
evaluating ZYNLONTA in combination with rituximab to treat relapsed or refractory (r/r) follicular lymphoma (FL) and the Phase 2, single-arm, open-label, multicenter trial of ZYNLONTA to treat r/r marginal zone lymphoma (MZL) led by the Sylvester Comprehensive Cancer Center at University of Miami have shown promising
More news about: ADC Therapeutics SA
Jan 08, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although the press release described the data in positive terms, the press release reported that adverse events occurred in two patients,
More news about: Pomerantz LLP
Jan 08, 2026, 08:45 ET VolitionRx Announces Breakthrough Clinical Data for Nu.Q® Vet Cancer Test in Cats
multi-national epigenetics company, announces results from a clinical study demonstrating the high accuracy of its Nu.Q® Vet Feline assay in detecting lymphoma in cats, the most common cancer in the species1. At 100% specificity, i.e. no false positives, the assay detected over 80% of feline lymphomas2
More news about: VolitionRx Limited
Jan 08, 2026, 07:15 ET ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In
More news about: ADC Therapeutics SA
Jan 07, 2026, 10:32 ET How $594B in Precision Tech is Cracking the Metastatic Cancer Code
LYMPHIR in the U.S. in December 2025 following FDA approval for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy, marking the first new systemic treatment option for CTCL patients since 2018. Management estimates the
More news about: USA News Group
Jan 07, 2026, 08:45 ET Curis Announces Pricing of Private Placement Totaling up to $80.8 Million in Gross Proceeds
inhibitor. Emavusertib is currently being evaluated in the TakeAim Lymphoma Phase 1/2 study (CA-4948-101) of emavusertib in combination with the BTK inhibitor ibrutinib in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) and in a Phase 2 study (CA-4948-203) of emavusertib in
More news about: Curis, Inc.
Jan 06, 2026, 03:19 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
BGB-16673 developed by BeOne Medicines | Chronic lymphocytic leukemia/small lymphocytic lymphomaA BTK-targeting chimeric degradation activation compound (CDAC), administered once daily orally to treat relapsed or refractory CLL and
More news about: Clarivate Plc
Jan 06, 2026, 03:07 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
BGB-16673 developed by BeOne Medicines | Chronic lymphocytic leukemia/small lymphocytic lymphomaA BTK-targeting chimeric degradation activation compound (CDAC), administered once daily orally to treat relapsed or refractory CLL and
More news about: Clarivate Plc
Jan 05, 2026, 21:08 ET The Inner Circle acknowledges, Sinisa Dovat, MD, Ph.D. as a Pinnacle Lifetime Member
in pediatric hematology and oncology was conducted at the University of California, Los Angeles. He also holds a Ph.D. in molecular pathogenesis of lymphoma from the University of Novi Sad and is board certified in pediatric hematology-oncology.His career is marked by significant accomplishments,
More news about: The Inner Circle
Jan 02, 2026, 16:05 ET Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
targeting indications in multiple high unmet need cancers, including in multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL). For more information about our people, science and pipeline, please visit
More news about: Karyopharm Therapeutics Inc.
Jan 02, 2026, 16:05 ET ADC Therapeutics Announces New Employee Inducement Grant
accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In
More news about: ADC Therapeutics SA
Jan 01, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT
efficacy of ZYNLONTA® in combination with the bispecific antibody glofitamab (COLUMVI®) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL)." Although the press release described the data in positive terms, the press release reported that adverse events occurred in two patients,
More news about: Pomerantz LLP
Dec 29, 2025, 19:45 ET Dr. Lu Xianping, Founder, Chairman of Chipscreen Biosciences named the Chinese mainland winner of the EY Entrepreneur Of The Year™ 2025 awards
product to be globally licensed out. It filled a critical gap in treating peripheral T-cell lymphoma in China and has extended new hope to patients with breast cancer, adult T-cell leukemia, diffuse large B-cell lymphoma and other malignancies. Chiglitazar Sodium, developed over 19 years for Type 2 diabetes,
More news about: Shenzhen Chipscreen Biosciences Co., Ltd.
Dec 28, 2025, 21:24 ET Senhwa Biosciences Aims at Multi-Billion Dollar Global Market with CX-5461 Combined with ADC "Blockbuster" Therapy
2Phase 1b/2 Trial of Pidnarulex in MYC Aberrant LymphomaUp to 50 subjectsPhase 1b: 36Phase
More news about: Senhwa Biosciences, Inc.
Dec 25, 2025, 03:45 ET China's First Domestic Anti-CTLA-4 Monoclonal Antibody, Innovent's TABOSUN® (Ipilimumab N01 Injection) Received NMPA Approval
scope for TYVYT® (sintilimab injection) includes:For the treatment of relapsed or refractory classic Hodgkin's lymphoma after two lines or later of systemic chemotherapy;For the first-line treatment of unresectable locally advanced or metastatic non-squamous
More news about: Innovent Biologics
Dec 23, 2025, 16:30 ET Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
receptor-directed immunotherapy, in the U.S. in December 2025 for the treatment of adult patients with relapsed or refractory Stage I–III cutaneous T‑cell lymphoma (CTCL) after at least one prior systemic therapy;Executed service agreements with the three leading U.S. pharmaceutical wholesalers to distribute
More news about: Citius Oncology, Inc.
Dec 23, 2025, 16:30 ET Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
pivotal year for Citius as we successfully launched LYMPHIR following its FDA approval, marking the first new systemic therapy for cutaneous T-cell lymphoma (CTCL) patients since 2018. This milestone reflects our ability to execute and our commitment to delivering impactful treatments for patients with
More news about: Citius Pharmaceuticals, Inc.
Dec 19, 2025, 07:55 ET Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
89.8% overall response rate and 77.6% complete response rate across 49 efficacy-evaluable patients with relapsed/refractory diffuse large B-cell lymphoma. The combination demonstrated strong efficacy in both relapsed (100% ORR, 91.7% CR) and primary refractory populations (80% ORR, 64% CR) while maintaining
More news about: Equity Insider
Dec 19, 2025, 07:44 ET Immunotherapies Replacing Chemotherapy as Blood Cancer Market to Hit $13B by 2030
in patients with Richter transformation, a rare, often fatal, transformation of chronic lymphocytic leukemia into an aggressive lymphoma, mostly diffuse large B-cell lymphoma," said Dr. Judith Klimovsky, Executive Vice President and Chief Development Officer of Genmab. "We are deeply committed to
More news about: USA News Group
Dec 18, 2025, 07:30 ET Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
HyBryte™ (SGX301 or synthetic hypericin sodium) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide.
More news about: SOLIGENIX, INC.
Dec 17, 2025, 08:45 ET Volition Issues Business Review 2025
peer-reviewed pre-analytics paper. We have subsequently completed our first clinical study to detect lymphoma in cats and look forward to publishing the results early in 2026, a development which will unlock a $5 million contractual milestone payment in due
More news about: VolitionRx Limited
Dec 17, 2025, 07:30 ET Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
billion in 2020 and projected to reach as much as $40 billion by 2027. The success of HyBryte™ in targeting malignant T-cells during cutaneous T-cell lymphoma (CTCL) clinical trials is a promising indicator of the ability of SGX302 to provide a much-needed approach for the treatment of mild-to-moderate psoriasis,
More news about: SOLIGENIX, INC.
Dec 16, 2025, 20:00 ET Antengene Expands XPOVIO® Indications in Malaysia with Approval in Diffuse Large B-cell Lymphoma
New Drug Application (sNDA) for XPOVIO® (selinexor) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after at least 2 lines of systemic therapy, who are ineligible for autologous stem cell transplant.
More news about: Antengene Corporation Limited
Dec 12, 2025, 16:29 ET Oklahoma Proton Center lauds results of groundbreaking clinical study
treatment. The center treats over 750 patients a year across multiple disease sites including head and neck, brain, breast, prostate, lung, esophageal, lymphoma, sarcoma, and pediatric cancers. For more information about proton therapy or to see if you are a candidate please visit
More news about: Oklahoma Proton Center